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Background: The World Health Organisation has designed a pregnancy registry to investigate the effect of
maternal drug use on pregnancy outcomes in resource-limited settings. In this sentinel surveillance system, detailed
health and drug use data are prospectively collected from the first antenatal clinic visit until delivery. Over and
above other clinical records, the registry relies on accurate participant reports about the drugs they use. Qualitative
methods were incorporated into a pilot registry study during 2010 and 2011 to examine barriers to women reporting
these drugs and other exposures at antenatal clinics, and how they might be overcome.
Methods: Twenty-seven focus group discussions were conducted in Ghana, Kenya and Uganda with a total of 208
women either enrolled in the registry or from its source communities. A question guide was designed to uncover the
types of exposure data under- or inaccurately reported at antenatal clinics, the underlying reasons, and how women
prefer to be asked questions. Transcripts were analysed thematically.
Results: Women said it was important for them to report everything they had used during pregnancy. However, they
expressed reservations about revealing their consumption of traditional, over-the-counter medicines and alcohol to
antenatal staff because of anticipated negative reactions. Some enrolled participants' improved relationship with
registry staff facilitated information sharing and the registry tools helped overcome problems with recall and naming
of medicines. Decisions about where women sought care, which influenced medicines used and antenatal clinic
attendance, were influenced by pressure within and outside of the formal healthcare system to conform to conflicting
behaviours. Conversations also reflected women's responsibilities for producing a healthy baby.
Conclusions: Women in this study commonly take traditional medicines in pregnancy, and to a lesser extent
over-the-counter medicines and alcohol. The World Health Organisation pregnancy registry shows potential to
enhance their reporting of these substances at the antenatal clinic. However, more work is needed to find optimal
techniques for eliciting accurate reports, especially where the detail of constituents may never be known. It will also be
important to find ways of sustaining such drug exposure surveillance systems in busy antenatal clinics.
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Pregnancy exposure registries are observational studies
measuring the association between drugs taken during
pregnancy and the pregnancy outcome [1]. They make im-
portant contributions to evidence on the safety of medi-
cines in pregnancy, particularly as this vulnerable
population is rarely included in clinical trials [2]. There is a
specific need to establish the safety profile of life-saving
therapies in countries with a high burden of diseases such
as malaria, TB and HIV/AIDS, so that pregnant women
are neither denied access to a safe drug nor exposed to an
unsafe drug. For instance, with the recent rapid scale up in
access to artemisinin-based combination therapies (ACT),
effective pharmacovigilance during pregnancy is important
as these drugs are contraindicated in the first trimester
[3,4]. There is also much to be learnt about the safety ofFigure 1 Flow diagram of WHO pregnancy registry procedures.non-prescription medicines, including herbs, which are
widely used but rarely studied [5-7].
Data about the prevalence of birth defects, including
those related to substances used post-conception, are gen-
erally lacking in resource-limited settings (middle and low
income countries) so the World Health Organisation
(WHO) designed a registry suitable for implementation by
national health authorities in these contexts for routine
surveillance [8,9]. The WHO registry, which is neither dis-
ease nor drug-specific, involves the prospective collection
of detailed health and exposure data from a woman's first
antenatal clinic (ANC) visit until delivery (Figure 1). As
data accumulate within countries or regions, it is expected
that the risk of specific drug exposures as determinants of
maternal and neonatal outcomes may be quantified. In
addition, the registry is intended to help build capacity for
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care systems. This could include training ANC staff about
the importance of obtaining a good treatment history
from pregnant women, collecting various indicators of
maternal and new-born health, and strengthening referral
systems for babies born with poor health.
As with all pharmacoepidemiologic studies the success
of the WHO registry relies, largely, on the accuracy of
exposure, outcome and covariate data [10]. In countries
where there is a relatively poor infrastructure for main-
taining institutional medical, prescription or dispensing
records, it is difficult to derive objective measures of
medical history and drug use [11]. Maternal reports may
be the only source of these data, particularly for medi-
cines obtained from private clinics, shops and traditional
practitioners. Methodological research shows that demo-
graphic characteristics (such as age and socio-economic
indicators), recall abilities, perceptions about the signifi-
cance or relevance of the information, anticipation of
consequences, and the ability to articulate a response,
are potential factors involved in shaping patients' or re-
search participants' reporting of health problems and
medicine use [10,12,13]. The way questions are posed
can also influence responses. For instance questionnaires
that include indication-for use and drug-specific questions
increase prevalence estimates for drug use compared to
open-ended questions [14]. As barriers to accurate and
complete reporting are likely to be context-specific it is
important to investigate these in the area where research
is conducted, such that relevant measures may be taken to
improve data quality.
A qualitative component was included in the WHO
registry pilot study in Ghana, Kenya and Uganda to exam-
ine the factors that either enabled or hindered the process
of creating and maintaining a successful registry in low
and middle-income settings. Specifically, it sought to ex-
plore, from pregnant women's perspectives, barriers to
their reporting, and thereby staff recording, of drug use
data in the registry and how these might be overcome;
what types of information are under- or inaccurately re-
ported at ANC visits, the underlying reasons, and how
women would prefer to be asked questions. This paper de-
scribes the results of these research questions to inform
optimal implementation of pregnancy registries by health
authorities in similar contexts.
Methods
We employed a qualitative study design, using focus
group discussions (FGDs) to collect the data. These were
nested within a WHO registry pilot study and conducted
between July 2010 and August 2011. In each registry site
a sample of women attending their first ANC visit were
enrolled. ANC nurses in the registry teams were given
standardised training in how to elicit information onmedical histories and medicine use from enrolled women
using a data collection tool which complemented the
existing ANC records [8]. A similar tool, with additional
fields related to the birth outcome, was used at the time of
delivery. Women were also encouraged to maintain a writ-
ten record of the names of medicines they had used (in
notebooks), or collect samples or packets in plastic enve-
lopes supplied. These were then to be brought to the site
at routine ANC follow-up visits to help registry staff make
an accurate record.
Qualitative study areas, population and sampling
The study population for this qualitative component in-
cluded two main categories of women 1) women of all
ages who had been enrolled in the WHO pregnancy regis-
try pilot study being conducted at selected sites in Ghana
(Dangme West District Hospital), Kenya (Webuye District
Hospital) and Uganda (Iganga District Hospital) and 2)
women of child-bearing age, who had experienced at least
one pregnancy, living in the communities or catchment
areas from which participants for the registry were drawn.
The latter category was included to potentially detect in-
fluence of the registry methods on reporting. Each site
was situated in a rural or semi-rural (small town) location.
National figures for women's use of an ANC for at least 4
visits during pregnancy were 78% in Ghana (2008), 47% in
Kenya (2009) and 48% in Uganda (2011); 55% (2008), 44%
(2009) and 58% (2011) of women respectively are attended
to by a skilled birth attendant during delivery; for 2011 the
prevalence of HIV (age 15–49) and annual number of
malaria cases are 1.5% and 1,041,260 for Ghana, 6.2 and
1002805 for Kenya and 7.2% and 231,873 for Uganda re-
spectively [15].
There were 12 strata of FGDs, as participants were
stratified by country, whether enrolled in the registry or
from the registry's source community, and < or ≥24 years
old (the latter because younger women often feel less
comfortable in expressing themselves in the presence of
older women [16]). Sampling was purposive as regards the
strata and where community participants resided in relation
to the respective ANCs. Those enrolled in the registry were
accessed through liaison with the pilot registry ANC study
staff teams, while women in the source community groups
were recruited within the catchment areas of each antenatal
clinic through households and community groups such as
markets. Two to 3 FGDs were to be conducted per strata,
with a minimum of 6 participants in each.
Study conduct, data management and analysis
Senior local social scientists (LY, OE, LMA) supervised
the field conduct of FGDs by teams trained according to a
manual and standard operating procedures developed by
an international coordinator (ENA). The original English
version of the FGD question guide was translated and pre-
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ology was locally appropriate. Topics included experiences
and perceptions about treatment-seeking in pregnancy,
poor birth outcomes, maintaining health and treatment
records, the pregnancy registry and reporting information
at the ANC. As recall ability is related to the time since
exposure to a medicine or other substance it was also im-
portant to understand the influences on seeking adequate
antenatal care, particularly the first ANC visit, and the
types of medicines used. The FGDs were held close to the
ANC but in a private space. Audio recordings of each
FGD were transcribed directly into English using a
meaning-based method, checked for quality and imported
into NVivo 9 (QSR International Pty Ltd, 2011). ENA and
each country social scientist co-coded at least 2 transcripts
(deductively, using the research questions, and induct-
ively) to agree on an initial coding framework before ENA
completed coding for all countries. Each transcript was read
several times before relevant text was examined for repeat-
ing concepts (codes) which were labelled and grouped into
categories and themes reflecting the underlying meaning
behind statements [17]. Quotes that represented the cat-
egories and themes were then selected for inclusion in this
manuscript. Code counts were also used to express the
size of some categories.
Ethical considerations
Approval from the ethical committees or boards of the
following institutions was obtained before the WHO pilot
registry study started in each respective country: the
WHO, Ghana Health Service, Moi Teaching and Referral
Hospital, Makerere University Faculty of Medicine, and
the Uganda National Council for Science and Technology.
The University of Cape Town Human Research Ethics
Committee also approved the analysis plan. Informed con-
sent processes and forms for the FGDs were available in
the local languages and, though information could be
explained in a group, each woman met with a facilitator
to confirm consent. Participants were informed about
who would have access to the data collected, that refusal
to participate or withdrawal of consent wouldn't affect
their medical care, and that they did not need to discuss
anything they were not willing to. No participant with-
drew consent. Refreshments were provided during FGDs.
Results
Twenty-seven FGDs were conducted across the 3 study
sites with a total of 208 women (Table 1). Ghana was un-
able to achieve 2 FGDs for registry participants and com-
pensated by enrolling more women in the community
FGDs. The qualitative analysis revealed three themes: "fac-
tors directly shaping reporting of exposures at the ANC
(allopathic and traditional medicines, and alcohol) "," in-
fluences on formal antenatal care" and "the social contextof pregnancy healthcare-related behaviour". Categories
within these themes included: "importance of reporting",
"negative consequences of reporting", "memory", "ability to
name medicines", "special relationship with registry staff
and registry-specific tools facilitates information sharing;
"good use of the ANC", "poor use of the ANC" (with their
codes); "pressure from all sides to conform to certain be-
haviours in pregnancy and "desire, and responsibility, for
having a healthy baby". These are presented diagrammat-
ically in Figure 2, while differences between the strata are
described below.
Factors directly shaping reporting of exposures at the
ANC (allopathic and traditional medicines, and alcohol)
Two large categories within this theme (across all countries,
ages and whether in the community or registry groups)
were conflicting; women said that it was important to re-
port everything relating to their health at the ANC for their
own and their baby's benefit (31% of relevant codes). How-
ever, this could have a negative reaction from the health
workers as they risked being scolded and sometimes humil-
iated in front of others (28% of relevant codes). This per-
ceived importance, but potential negative consequences,
of reporting are reflected in the quotes below:
“[ANC staff] are the ones who will know the
medicines to give. So whether you are scolded or not
you have to tell them because, when you [are] scolded
and given drugs to cure yourself, you are better off "
[Older community participant, Ghana]“Some nurses don’t know how to handle patients so
you just fear that she may scold you in front of
people. So you just keep quiet even if you have a
problem” [Younger community participant, Kenya]“[You have to report] the drugs you took before
starting antenatal [visits] as, if you have a drug that is
not good, she would tell you next time you are
pregnant don't take it again.
[Later]: sometimes when you say it the nurses may
not be patient with you, so you are afraid that when
you tell her she will be annoyed with you” [Older
enrolled participant, Ghana]
Therefore, while women said that they should (or did),
report everything, they often later said that they would
not (or did not). The conversations reflected a general
fear of health workers' attitudes, with older women in
Ghana also saying that it was easier to converse with
older nurses who were more polite. When asked about
substances they had used during pregnancy, women
across all strata said they particularly feared reporting
their use of traditional medicines, to a lesser extent
Table 1 Focus group discussion (FGD) participants in each strata
Ghana Kenya Uganda
Registry Community Registry Community Registry Community
Age strata (years) <24 ≥24 <24 ≥24 <24 ≥24 <24 ≥24 <24 ≥24 <24 ≥24
Number of FGDs 1 1 2 4 2 2 2 2 2 3 3 3
Number of participants per strata 9 9 16 40 13 12 20 21 11 19 19 19
Mean age (range) in years 21 (18–23) 31 (26–41) 21 (18–23) 38 (24–72) 20 (NK) 30 (NK) 23 (NK) 30 (NK) 21 (18–23) 27 (24–35) 21 (17–23) 31 (25–40)
Mean number of children 0 2 1 4 0 2 1 3 1 2 1 3





















Figure 2 Summary of the influences on participant reporting in the World Health Organisation drugs exposure pregnancy registry.
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merous descriptions of personal and others' experiences
of being scolded for using these, including women being
accused of using unreported traditional medicines dur-
ing labour to account for a difficult birth.
There were exceptions, with sporadic descriptions of
good relationships with ANC staff in general, where use
of such substances was discussed. Moreover, there was
limited mention in Ghana and Uganda of ANC staff en-
dorsing the pregnant women's use of traditional medi-
cines, and of participants' perceptions that nurses accept
its benefits:
“I know traditional medicines work better than what
the modern health workers tell us ……When you tell
them they don’t accept [it], yet they also use [it] and
they will never tell you that they [do]” [Younger
community participant, Uganda]
Smaller categories in this theme related to memory and
the ability to name medicines (12% of relevant codes).
There was little explicit mention of these impacting on
reporting. In fact, women in community FGDs in all coun-
tries and age groups said they do remember everything
taken during pregnancy: “They remember alright but they
will not say” [Older community participant, Ghana]. How-
ever, these concepts were sometimes implicit in the tran-
scripts; women talked about substances they had used but
couldn't remember or know their names and ingredients,
particularly herbs.
Suggestions from women about how they could more
readily report at the ANC what medicines or other sub-
stances they had used reflected the dominance of fear of
reporting as a barrier. Thus they recommended that
nurses be more understanding/empathetic. In Uganda,where this was discussed at length, enrolled women ex-
plained how they were able to forge a special relationship
with the friendlier, dedicated registry nurses who sought,
and would accept, full disclosure. Similarly, when the regis-
try rationale and method was explained to them, commu-
nity women considered that being enrolled would help
them report such information. There was, however, some
indication that this improved attitude of registry nurses did
not always extend to those women not enrolled:
Participant: You don’t talk about [Waragi, a local gin]
here because you may find a health worker who may be
harsh on you why you took [it].
Facilitator: What about here in the registry, would you
still not talk about Waragi?
Participant: Here I know I have my nurse who works
upon me, so … if she asks me I can let her know that I
take a little Waragi, not to be [a] drunkard.
Facilitator: What of the local herbs?
Participant: I also have to tell her.
Facilitator: Won’t she shout at you?
Participant: No, she doesn’t shout at me
[Younger registry participant, Uganda]
“[Registry nurses] welcome you and give you a lot of
care and even ask how you are feeling. But if another
person who is not [enrolled in the registry] comes
they just look at her like this, yet they are the same
nurses who welcomed you well” [Older registry
participant, country anonymised]
The registry also facilitated information sharing by en-
couraging enrolled women to collect names or examples
(e.g. leaves, packets) of what they had used, with com-
munity groups also acknowledging this could be
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can’t remember the name, you will come back and pluck
it for the doctor, that this [is] the drug I have taken"
[Older community participant, Ghana]. In addition,
women said that making antenatal care more accessible,
particularly to those in rural areas, would be beneficial
for reporting:
"I also support the home visit because the atmosphere
will be conducive to reveal all your health matters, as
you are relaxed. Rather than the hospital where you
are in a hurry to clear the line for next patient and
allow the busy nurse [to] continue with her ever busy
schedule" [Older registry participant, Kenya]
Influences on formal antenatal care
The analysis showed two categories related to formal
antenatal care which impact on medicines used in preg-
nancy and the recall period for reporting; good or poor
use of the ANC. The transcripts revealed that good use
relied on women seeing the value of going to the ANC
if, for instance, it was considered better than alternatives
(e.g. traditional care givers). This was apparent in all strata
and was particularly important to women who had experi-
enced a previous poor pregnancy outcome while relying
on other care options. Some women had practical (includ-
ing financial) or moral support from family or friends to
attend. However, while there was limited evidence of preg-
nancy testing and ultrasounds being obtained at private fa-
cilities early in pregnancy in all countries, it was common
in all strata to delay attendance at the government facility
until the second or third trimester. Many women said they
delayed attending the ANC until they experienced illness,
while others intended to go only once to collect an ANC
card/book. This was essential in case they needed to use
the labour ward, as they anticipated abuse for not register-
ing if there were problems during delivery. Poor attend-
ance was also due to negative perceptions of the ANC (an
expectation of being ill-treated by staff, sitting for a long
time in a queue or having to undergo an HIV test that
they did not want). The narratives showed that younger
women were particularly vulnerable to inadequate formal
ANC care. They were more likely to have not recognised
the pregnancy signs and symptoms, have had less access
to support, may have hidden the pregnancy initially, or
attempted abortion.
Traditional birth attendants were consulted in all three
countries by both those who did and did not attend the
ANC regularly, particularly for positioning the baby in
the womb. Other options for healthcare during preg-
nancy included drug shops, traditional healers or herbal-
ists (though these were all less common as they were
not considered pregnancy experts), family or community
members, and spiritualists. Traditional medicines werewidely used across all strata (58% of codes relating to
substance-use in pregnancy). Ingested traditional medi-
cines, including leaves and roots sometimes mixed in
clay or soil, were taken for fever/malaria, constipation,
heartburn, to treat or provoke vomiting (the latter to
clean dirt or illness from the mother or baby), anaemia,
to prepare for birth (by cleaning the womb of sexually
transmitted diseases or for softening the pelvic bones
and position the baby correctly), to prevent miscarriage,
for the mother's energy, for growth/strength of the baby,
or as an abortificant. Some of these medicines were
named (typically those herbs picked by oneself or a rela-
tive), while others were not (typically concoctions pre-
scribed by a healer). There was a particular discussion
among older women in Ghana about not liking medi-
cines from the ANC (such as iron and antimalarials),
with one woman saying that, even if she attended the
ANC to prevent conflict or condemnation, she did not
trust such medicines:
“I will go to the health facility alright. If I don’t go you
will tell me [off]. So I will go and when I am given the
drugs I will use them as pillows (put them aside). It’s
the traditional ones that I take, and [I] am strong too”
[Older community participant, Ghana]
Participants in various FGDs reported using the fol-
lowing allopathic medicines during their pregnancies:
ibuprofen, aspirin, indomethacin, antimalarials, penicillin
and amoxicillin. Some of these were inadvertently taken
before the pregnancy diagnosis. For antimalarials this
early exposure could reflect conflated narratives about
fever, malaria and pregnancy signs/symptoms apparent
in all strata:
“I used to miss my periods for even three months, so
when it happened I thought it was just malaria. I
bought some tablets then came to hospital. It is then
that they confirmed that I was pregnant” [Younger
community participant, Kenya]
Women rarely mentioned traditional medicines as the
cause of poor birth outcomes apart from those specific-
ally used for attempted abortions. Poor outcomes were,
however, said to be predominantly due to spiritual at-
tacks (20% of relevant codes), but also the use of over-
the-counter drugs (5%), prescribed contraceptives (10%)
or being passed directly from parent to child (16%). There
was confusion about alcohol throughout all strata. Some
women felt that drinking it could harm the mother or
baby, but there was evidence of others endorsing it, gener-
ally in small quantities, to clean the womb or baby of
semen, infection or ingested substances (such as clay), and
for ensuring the baby had nice whites of the eyes. Its use
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was also used for enhancing women’s appetites or sleep,
and for easing labour:
“People say that Akpeteshie (a local gin), is not good.
Well I confess I drink Akpeteshie when I am pregnant
because they say that, if you are pregnant and you
drink it, your baby will be clean. If you are pregnant
and you drink alcohol, you do not get drunk, no
matter the quantity you drink” [Younger community
participant, Ghana]Participant: You should take Guinness (a strong beer)
Facilitator: Why Guinness?
Participant: They say when you take it during delivery
it cleans the womb, so at delivery there is no stomach
ache, the womb is washed clean.
Facilitator: How much do you take?
Participant: You take a glass. You take towards delivery,
or even during pregnancy, but just once in a while you
take the small Guinness.
Facilitator: Who says this?
Participant: Just people. But not the doctors of course,
but women who have delivered previously and have
actually used it to avoid the pain at delivery
[Older registry participant, older, Kenya]
Social context of pregnancy healthcare-related behaviour
We observed two categories relating to societal influences
on women's healthcare-related behaviour during pregnancy;
an apparent pressure to conform to what was expected by
the ANC, the family and community, and responsibility for
a healthy baby. Underpinning the themes reported above
was an explicit or implicit understanding that women were
expected by the government ANC to attend ANC regularly,
to largely abstain from self-medicating, and to report their
health and treatment use accurately. Meanwhile, women in
all strata showed how they may also have to adhere to cer-
tain culturally-dictated behaviours to ensure a healthy
pregnancy, and manage the pregnancy at home. The latter
was compounded by problems accessing formal care. Ex-
pectations of, or advice from, the different parties involved
were often conflicting, and involved power relationships.
For instance, the conversations with younger women
revealed that they were sometimes pressurised by older
women in the community to behave a certain way or dis-
regard institutional recommendations for formal care.
Over and above their own desires for a healthy baby, con-
versations also reflected women's responsibilities for pro-
ducing babies acceptable to the father, his family, and/or
the community. All FGDs showed how women must be
careful about how they conduct themselves in public,
what they eat or what medicines they use, as these may
dictate whether a baby is born healthy. Despite theseconsiderations, she may still be blamed for producing a
child with a birth defect. These societal pressure categor-
ies are demonstrated below:
“The old women … advised me that it is not necessary
to go early [to the ANC] because you will be going
there all the time. I told them that I want to go to the
health centre because I was feeling lower abdominal
pain. Still they rejected me and could tell my husband
not to give me money for going there because my
pregnancy was still young. So I just came when he
gave me money to eat” [Younger registry participant,
Uganda. Attended ANC first at 5 months]"In my hometown, they say pregnant women should
not engage in a lot of things, so if you turn a deaf ear
to what the tradition says and there [are] gods in your
town, [you] could have a child with a defect.
Therefore if you live in such a town you should be
very careful until you deliver" [Older community
participant, Ghana]"I also have a sister-in-law who gave birth to a child
with a big head but the husband chased her and told
her that he doesn’t produce babies with big heads"
[Older registry participant, Uganda]"When one is pregnant you don’t have to take
alcoholic drink because it affects the babies in the
womb and when you give birth the babies will not
look attractive and people would not give you a
helping hand in carrying him or her" [Community
participant, older, Ghana]
Discussion
This qualitative study found that women desired, and felt
responsible for, carrying a healthy baby to term. However,
despite largely deeming all health-related information dur-
ing pregnancy important to report at the ANC to help en-
sure a good outcome, they could not always recall or give
exact details of what substances they had used. Moreover,
the pressure to conform to both formal and traditional
pregnancy care options, or a practical need to combine
such care, led to a common use of substances with un-
known effects in pregnancy, including traditional medi-
cines, over-the-counter medicines and alcohol. Such
substances were not always reported easily at the ANC as
women generally feared being admonished by staff. While
pregnancy registries could play a valuable role in building
knowledge about the safety of medicines used in preg-
nancy in resource-limited areas, they are dependent on
valid and reliable data. If there is significant measurement
error of exposures, outcomes or confounders, associations
will be incorrect and pregnant women will not get
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fore, important to consider all these barriers to accurate
participant reports so that socially-contextualised solu-
tions may be sought.
This present finding that various factors influence
women’s willingness or ability to seek antenatal care is
consistent with results of previous studies [18-20]. As well
as increasing the risk for complications, those not adher-
ing to national recommendations for such care may be
less likely to receive appropriate advice about safe sub-
stance use. This will be exacerbated should women not
recognise, or choose to hide their pregnancy, or lack fam-
ily or community support to seek appropriate healthcare,
particularly in younger women [21,22]. However some
women indicated that the advice they receive about sub-
stance use in pregnancy could be inconsistent; midwives
sometimes endorsed the traditional medicines and alcohol
that women largely expected to be vilified for reporting.
This confusing situation for pregnant women probably re-
flects the staff's own dilemmas with interpreting mixed
messages when living and working in a context where
traditional medicine is an embedded practice and some-
times the only readily-available option.
The registry fostered a relationship between pregnant
women and ANC staff where some women said they
were more able to report everything they had used. In-
deed, preliminary data from the registry database shows
that use of herbal medicines and alcohol were reported
in all countries. However, this qualitative study cannot
confirm whether the extent of such reporting is higher
than in non-registry settings or reflects the true experi-
ence of enrolled women. If the registry did enhance
reporting, this may have been influenced by other fac-
tors. For instance, the informed consent process ex-
plained why it was important to report everything, and
the data collection tool required ANC staff to explicitly
ask participants about their use of traditional and herbal
medicines and alcohol, with space to record these de-
tails. The latter is in contrast to most standard ANC re-
cords or booklets in these countries.
There was an indication that an improved relationship
between patients and staff may not extend to other
women attending the ANC who were not enrolled in the
registry. Enrolling all women at a particular facility in a
drug exposure surveillance system would ensure that the
community does not become resentful of the project or
those included. However, whether it is feasible for any
woman presenting at a busy ANC to receive the same at-
tention, and feel free to report her experiences accurately,
needs further investigation. As a minimum, registry sites
should support the various interventions to encourage re-
spectful maternity care, including improved working con-
ditions for ANC staff [23]. Staff should also be guided in
how to collect data on substances whose use they aretypically trained to discourage. Emphasis should be placed
on conveying messages about known risks or the fact that
there are limited safety data for some substances, so
that pregnant women understand the rationale for dis-
couraging their use [24-26]. Much could be learnt from
research on smoking in pregnancy, to encourage transpar-
ency and trust in ANC communications about potentially
risky behaviour [27].
Poor ANC attendance will undoubtedly impact nega-
tively on registry participants remembering their health
and treatment experiences accurately. There is a dearth
of research relating to the validity of pregnant women's
recall of non-prescription drugs in general, and very lit-
tle about self-reported medical histories and treatment
use in resource-limited settings. However, it is clear that
some questioning techniques are better than others [28].
For instance, structured questions indicating specific
health conditions and names of treatments are likely to
increase the sensitivity of their detection compared with
open questions [10,14]. As detailed questionnaires place
a burden on staff, the limited questions incorporated
into the WHO registry pilot study reflected its intention
to be adopted by busy ANCs. This may have led to
under-reporting of drug exposures and developing an
optimal questioning method in these contexts requires
further work. Antenatal records could also be designed
to encourage elicitation and recording of drug exposures
by staff as a routine practice. Pictures of typical health
complaints and medicines may be needed in areas with
low literacy, and registry teams could learn from other
pharmacoepidemiologic interview techniques, whereby
participants are helped to identify the timing and dur-
ation of medicine use [29]. These may be particularly
useful in areas where women present late in pregnancy
for their first ANC visit.
Women enrolled in the registry were happy to keep
records or collect samples of what they had taken. How-
ever, the constituents and doses of herbal remedies, such
as concoctions dispensed by traditional practitioners, are
often unknown by consumers [5]. It is theoretically pos-
sible that this information may even deliberately be with-
held for fear that consumers may then source their own
herbs. This problem of not knowing ingredients of such
substances is supported by preliminary registry findings
where these details were not always obtained. It may
therefore only be feasible to capture a binary yes/no for
herbal use in registries, to identify signals of potential
harm for later, more specific, studies. However, certain
concoctions are well known locally to be used in preg-
nancy and may represent a semi-standardised regimen in
some regions. If these were adequately recorded at the
ANC it may be possible to establish any associated risk of
harm. For allopathic medicines, registry sites could pursue
intra- and inter-institutional record linkages (with other
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and opportunities for innovative collaborations with other
local healthcare providers, including local private clinics
and traditional birth attendants. There may be scope for
participant referrals or data sharing, and exploring local
understanding of substances that are typically used or
prescribed.
This study was concerned with the complex field of
obtaining accurate reports from registry participants about
their exposures to medicines and other substances. Finding
appropriate questioning methods in pharmacoepidemiolo-
gical studies is methodologically challenging. For instance,
these participants voiced their fears of mentioning trad-
itional medicines, and yet they also considered them as
having less potential for causing poor pregnancy outcomes
compared to other perceived determinants, such as spirit-
ual attacks. The latter may reflect a global public perspec-
tive that complementary medicines are generally safe [30].
Judgements made by participants about the significance
of a health event or treatment, or its relevance to the situ-
ation, can impact on reporting [10,13], and substances con-
sidered by consumers as safe may potentially be deemed
irrelevant to report. Due to the lack of a gold standard for
participant reported data in pharmacepidemiology, it is
therefore important that qualitative methods be incorpo-
rated into any future work, to contribute to understanding
the nuances involved.
Limitations
We could not verify that the reports of women taking part
in these FGDs are accurate. Although the questions in the
FGD guide were applied in all FGDs, there were differ-
ences in how facilitators probed the answers. Therefore
some FGDs generated richer data which may impact on
the findings. Our results may not be generalizable to other
studies where the methods and context are very different.
Ghana was unable to achieve 2 FGDs in the registry par-
ticipants' strata, and there was an error during recruitment
whereby some women over the age of 51 were enrolled
into some of the 4 community FGDs. As the Ghanaian
FGDs had the richest data it is likely these issues did not
compromise the comparisons between sites.
Conclusion
There was widespread reported use of traditional medi-
cines in pregnancy in this study's population, and, to a
lesser extent, use of over-the-counter medicines and alco-
hol. The qualitative findings suggest that the WHO regis-
try methods could address some barriers to reporting
these at the ANC as it gave women tools to help overcome
problems with recall and naming of substances, and some-
times enhanced their relationship with ANC staff. Ques-
tioning techniques for women attending busy ANCs
where registries are implemented should be explored toidentify optimal approaches, especially for recording sub-
stances such as herbal concoctions where the detail of
constituents may never be known.
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